Related Experiment Videos
Pharmaceutical patents and price controls
1Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson 85721-0207, USA. vogel@pharmacy.arizona.edu
Clinical Therapeutics
|August 17, 2002
Summary
Pharmaceutical price controls undermine patent agreements, reducing profits available for research and development (R&D). This impacts future drug innovation and harms consumers globally by limiting new pharmaceutical options.
Area of Science:
- Pharmaceutical Economics
- Intellectual Property Law
- Health Policy
Background:
- World Trade Organization (WTO) mandates a 20-year patent life for pharmaceuticals.
- Patents are crucial for pharmaceutical innovation, protecting against easy imitation.
- Direct price controls can circumvent the economic intent of patent protection.
Purpose of the Study:
- To model the economic impact of pharmaceutical pricing and price controls.
- To analyze the effects of price controls versus no price controls on pharmaceutical output and pricing.
- To examine variations in price control policies across different countries.
Main Methods:
- Economic modeling of pharmaceutical demand and supply.
- Analysis of hypothetical pharmaceutical market dynamics.
- Extrapolation of price control effects.
Main Results:
- Pharmaceutical patents fund new product development.
- Price controls indirectly circumvent patent logic but shift economic costs internally.
- Reduced profits lead to decreased investment in research and development (R&D).
Conclusions:
- Price controls allow countries to bypass patent constraints without explicit violation.
- Reduced R&D funding due to price controls negatively impacts global pharmaceutical innovation.
- Consumers worldwide face a detriment from diminished R&D, leading to fewer new medicines.